Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity

NCT02464007 is registered in ClinicalTrials.gov with Sichuan Huiyang Life Science and Technology Corporation as lead sponsor.

NCT NCT02464007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02464007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity
Lead sponsor
Sichuan Huiyang Life Science and Technology Corporation
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2016
Completion date
November 30, 2024
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malignancies including melanoma, kidney, lung, colorectal, prostate, neuroendocrine tumor